NCT02303990View on ClinicalTrials.gov

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Metastatic Cancers
Interventions
DRUG

Pembrolizumab

RADIATION

Radiotherapy

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02303990 - RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Biotech Hunter | Biotech Hunter